The BRI3BP Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the SK-HEP-1 human hepatic adenocarcinoma cell line, featuring targeted disruption of the BRI3BP gene. This loss-of-function model enables investigation of BRI3BP??s role in apoptosis regulation and cell survival signaling in a liver cancer context.
The SK-HEP-1 cell line, established from the ascitic fluid of a patient with liver adenocarcinoma, is a widely used model for hepatocellular carcinoma research. Its origin from a malignant effusion and its rapid proliferation make it particularly suitable for studies of tumor cell survival, metastatic behavior, and response to therapeutic agents.
BRI3BP interacts with BRI3 to modulate apoptotic signaling, suppressing caspase activation and mitochondrial outer membrane permeabilization. In response to cellular stress or DNA damage, upstream regulators such as p53 and NF-??B may influence BRI3BP expression or activity, thereby controlling the balance of pro-apoptotic and anti-apoptotic Bcl-2 family members like Bax and Bcl-2. Disruption of BRI3BP is expected to release this negative regulation, sensitizing cells to apoptotic stimuli and promoting downstream caspase-9 and caspase-3 activation.
Knocking out BRI3BP in SK-HEP-1 cells creates a hepatic adenocarcinoma model with altered apoptotic threshold, enabling dissection of survival pathways critical for hepatocarcinogenesis. Given the host cell line’s relevance to liver cancer metastasis and vascular biology, this polyclonal knockout population provides a physiologically relevant platform to study how loss of anti-apoptotic signaling affects tumor cell behavior and drug sensitivity.
The BRI3BP Knockout SK-HEP-1 Polyclonal Cells support a variety of functional assays, including Western blotting for cleaved caspase-3, PARP, or Bcl-2 family proteins, flow cytometric quantification of apoptosis via Annexin V/PI staining, and caspase-3/7 activity measurements. Cell viability assays such as MTT can determine differential drug responses between wild-type and knockout populations, while RT-qPCR or RNA-seq enables transcriptional profiling of apoptosis-related genes. These cells are ideal for mechanistic studies of BRI3BP in hepatic cell survival, high-throughput drug sensitivity screens, and investigation of apoptosis-related disorders. For additional technical details or custom cell engineering services, please contact Ascent Research.
